Dr Reddy’s To Market Three Amgen Drugs in India
Dr Reddy’s and US-based biotech firm Amgen collaborated to market and distribute three Amgen medicines in India.
advertisement
Dr Reddy’s Laboratories today said it has inked a pact with US-based biotechnology firm Amgen to market its three drugs used to treat heart diseases and cancer in India.
The Hyderabad-based firm said it has entered into a strategic collaboration with Amgen to market and distribute three Amgen medicines in India in oncology and cardiology, Dr Reddy’s Laboratories said in a statement.
Under the terms of the collaboration, Dr Reddy’s shall undertake a full range of regulatory and commercial services to seek approval and launch the three drugs — Kyprolis, Blincyto and Repatha — in India.
Dr Reddy’s stock was trading at Rs 4,286.45 on BSE, up 2.18 per cent.
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)
- Access to all paywalled content on site
- Ad-free experience across The Quint
- Early previews of our Special Projects
Published: undefined